Skip to main content

Abdominal Pain

3
Pipeline Programs
6
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeksPhase 41 trial
Active Trials
NCT00310765Terminated18Est. Aug 2008
Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
1
1
Ketamine hydrochloridePhase 31 trial
Social Learning and Cognitive Behavioral TherapyPhase 21 trial
Active Trials
NCT00494260Completed200Est. Jun 2010
NCT06835504Not Yet Recruiting1,010Est. Oct 2029
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
AEGISN/A1 trial
Active Trials
NCT02436057Completed255Est. Dec 2015
CENTOGENE
CENTOGENEGermany - Rostock
1 program
Epidemiological Analysis for Hereditary Angioedema DiseaseN/A1 trial
Active Trials
NCT03558009Completed2,318Est. Apr 2022
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Hyoscine Butylbromide - TabletPHASE_31 trial
Active Trials
NCT02242305Completed302Est. Jul 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
PfizerPregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks
Human BioSciencesKetamine hydrochloride
Boehringer IngelheimHyoscine Butylbromide - Tablet
Human BioSciencesSocial Learning and Cognitive Behavioral Therapy
CENTOGENEEpidemiological Analysis for Hereditary Angioedema Disease
Angeles TherapeuticsAEGIS

Clinical Trials (6)

Total enrollment: 4,103 patients across 6 trials

NCT00310765PfizerPregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks

Pregabalin for Abdominal Pain From Adhesions

Start: Mar 2006Est. completion: Aug 200818 patients
Phase 4Terminated
NCT06835504Human BioSciencesKetamine hydrochloride

Morphine or Ketamine for Analgesia

Start: May 2026Est. completion: Oct 20291,010 patients
Phase 3Not Yet Recruiting
NCT02242305Boehringer IngelheimHyoscine Butylbromide - Tablet

Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort

Start: Nov 2008Est. completion: Jul 2009302 patients
Phase 3Completed
NCT00494260Human BioSciencesSocial Learning and Cognitive Behavioral Therapy

Managing Recurrent Abdominal Pain

Start: Nov 2003Est. completion: Jun 2010200 patients
Phase 2Completed
NCT03558009CENTOGENEEpidemiological Analysis for Hereditary Angioedema Disease

Epidemiological Analysis for Hereditary Angioedema Disease

Start: Sep 2018Est. completion: Apr 20222,318 patients
N/ACompleted
NCT02436057Angeles TherapeuticsAEGIS

Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform

Start: Jul 2014Est. completion: Dec 2015255 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.